Imagine if you could fix your sweet tooth with a drug instead of a drill. It could happen. Researchers have discovered that Tideglusib, a drug in clinical trials for Alzheimer’s and other neurological disorders, repairs cavities in mice by promoting the natural regrowth of tooth material. Humans could be next.
Today, when a cavity forms in a tooth, a dentist repairs it by drilling into the tooth to expand the hole, then patches it with a material made using a compound material that includes silicon or calcium-based aggregates. In the foreseeable future, that cavity could be repaired with a sponge soaked in Tideglusib, which stimulates the tooth’s own stem cells to create new dentine — the substance beneath tooth enamel that's eroded by decay when a cavity forms. The process takes about six weeks.
For perhaps the first time, patients suffering from Huntington’s disease have cause for hope. A recent trial conducted by researchers at University College London (UCL) indicates that an experimental drug may significantly suppress a mutated gene related to Huntington’s devastating degenerative effects.
It is estimated that about 30,000 people in the United States and 8,500 people in the UK currently suffer from Huntington's. The disease, which some patients describe as a mix of Alzheimer’s, Parkinson’s and ALS, is responsible for a dizzying array of symptoms. Patients first experience severe mood swings and depression, then face ever-worsening dementia and a gradual loss of motor control that ends in paralysis; the majority die about 10 to 20 years following its onset.
Many of us know about how dirty dishes led to the discovery of penicillin. But few know the story of the discovery of the drug that would kill scores of rats and save thousands of human lives.
In the early 1920s, cows across the Northern United States and Canada were dying after succumbing to major hemorrhaging—but no one knew why the hemorrhaging was occurring.
Researchers were effectively able to reverse the symptoms of type 2 diabetes in mice through the administration of a daily oral drug—with no ill side effects. This is the first time that a treatment has been able to “cure” type 2 diabetes. The research appears in the journal Nature.
People who suffer from migraines may be able to prevent them months in advance, thanks to an experimental new treatment delivered intravenously four times a year. If that sounds extreme, consider this: Migraines, which can be accompanied by nausea and vomiting, extreme sensitivity to light and sound, visual disturbances, numbness in extremities, and debilitating pain, affect up to 38 million people in the U.S. and cost $36 billion in lost productivity and health care costs every year. In other words, migraines are no ordinary headache.